| 3.9763 -0.334 (-7.74%) | 09-24 12:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.65  |
1-year : | 7.97 |
| Resists | First : | 5.69 |
Second : | 6.82 |
| Pivot price | 4.74 |
|||
| Supports | First : | 3.86 |
Second : | 3.21 |
| MAs | MA(5) : | 4.52 |
MA(20) : | 4.97 |
| MA(100) : | 4.71 |
MA(250) : | 3.36 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 21.4 |
| RSI | RSI(14): 32.2 |
|||
| 52-week | High : | 6.82 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRLD ] has closed below the lower bollinger band by 2.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 3.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.88 - 4.9 | 4.9 - 4.92 |
| Low: | 4.11 - 4.14 | 4.14 - 4.15 |
| Close: | 4.28 - 4.31 | 4.31 - 4.34 |
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Sun, 20 Sep 2026
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to S&P Global BMI Index - marketscreener.com
Sun, 20 Sep 2026
Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial - AD HOC NEWS
Thu, 17 Sep 2026
PRLD Initiated Coverage by JP Morgan -- Rating Set to Overweight - GuruFocus
Fri, 11 Sep 2026
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Sun, 23 Aug 2026
Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 76.4 (%) |
| Shares Short | 3,820 (K) |
| Shares Short P.Month | 3,290 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.29 |
| Profit Margin | -269.8 % |
| Operating Margin | -271 % |
| Return on Assets (ttm) | -27.2 % |
| Return on Equity (ttm) | -57.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.34 |
| Sales Per Share | 0.34 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -5.37 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 11.36 |
| Price to Cash Flow | -7.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|